Biotech | December 14, 2021
Samsung Biologics expands tie-up with AstraZeneca to include cancer therapy
The company will manufacture a cancer immunotherapy product from 2022
The company will manufacture a cancer immunotherapy product from 2022
State-of-the-art R&D facility designed to foster collaboration across world-class science ecosystem
Six-months follow-up of prevention trial showed 83% reduced risk of symptomatic Covid-19, with no severe disease or deaths
The Board of Directors of AstraZeneca Pharma India have approved the unaudited consolidated financial results of the company for the period ended September 30, 2021
The agreement sharpens the company’s focus on priority medicines in respiratory & immunology portfolio
This capability programme aims to upskill 5000 nurses across the country in the next year by converting the current modules into an e-learning one
The division is expected to grow to over a 100-member strong team by 2022
Rajiv Gandhi Cancer Institute (RGCI), Delhi one of Asia’s premier institutes becomes the first strategic partner to adopt and implement Project Chariot in patients across North India & Delhi NCR region
The company will shift 100 percent of its energy use to renewable sources for both power and heat by 2025 in order to achieve carbon neutrality
The filing includes data from PROVENT Phase III trial showing 77% reduction in risk of developing symptomatic Covid-19 with a long-acting antibody combination (non-vaccine)
Subscribe To Our Newsletter & Stay Updated
